Follow Us
© 2026 Arizent. All rights reserved.
IMGCAP(1)]
(Reuters) NEW YORK | Wed May 18, 2011 10:29am EDT – Global sales growth of prescription drugs could be cut in half over the next five years as lucrative brands lose patent protection and cheaper generics and emerging markets become the only significant growth drivers, according to a study by IMS Health.
For reprint and licensing requests for this article, click here.
As costs to treat serious conditions surge, employers must plan how to absorb budget-altering expenses ahead of time.
Bringing a procurement partner into the benefits planning process can offer greater insight and negotiation power, helping to reduce overall costs.
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
The legislation calls on Congress to lower prescription drug costs, shift subsidies directly to consumers, and enforce strict price transparency.
At Sun Life, offerings like paid family medical leave, sabbaticals and flexible work arrangements set top talent up to thrive.
